PolyNovo (PNV) H2 2024 earnings summary

Executive summary

• Achieved record FY24 revenue of AUD 104.8 million, up 57.5% year-over-year, with NovoSorb product sales at AUD 92 million, up 54.5% year-over-year, and strong global expansion and product adoption.

• Transitioned to profitability, reporting a net profit after tax of AUD 5.3 million versus a prior year loss of AUD 4.9 million, and positive operating cash flow of AUD 3.7 million.

• U.S. and Rest of World (ROW) sales saw significant growth, with U.S. up 49% to AUD 68.7 million and ROW up 73.3% to AUD 23.4 million compared to FY23.

• Expanded to 41 countries, with commercial sales in 29, over 50,000 patients treated globally, and 284 independent articles and abstracts published.

• Clinician-driven innovation and partnerships, including BARDA, underpin product development and market expansion.

Financial highlights

• Total revenue including BARDA was AUD 104.8 million, up from AUD 66.5 million in FY23.

• NovoSorb product sales rose 54.5% to AUD 92 million; BARDA revenue nearly doubled to AUD 11.2 million.

• U.S. sales reached AUD 68.7 million, up 49% year-over-year, with 197 new accounts added.

• Rest of world sales grew 73.3% to AUD 23.4 million, now representing 25% of global sales.

• Cash and cash equivalents stood at AUD 45.9 million at year-end.

Outlook and guidance

• No formal revenue or profit guidance provided; focus remains on growth and global expansion, with plans for Japan market entry in CY25 and India tenders/reimbursement in FY25.

• Continued investment in R&D, clinical evidence, and capacity expansion, including a new facility with AUD 26 million CapEx.

• Expectation of sustained high gross margins and operating leverage, but margin may moderate as lower-priced markets grow.

• U.S. remains a multi-year growth opportunity; India expected to be a major volume driver.

• Capex expected to rise in FY25 and FY26 for new manufacturing facility in Port Melbourne.